CNR ExploRA

Articolo in rivista, 2021, ENG, 10.3390/molecules26175227

An overview of peptide-based molecules as potential drug candidates for multiple sclerosis

Del Gatto A.; Saviano M.; Zaccaro L.

Institute of Biostructures and Bioimaging, CNR, Naples, 80134, Institute of Biostructures and Bioimaging, CNR, 80134, Naples, Italy, , Italy; CIRPeB, University of Naples "Federico II", Naples, 80134, CIRPeB, University of Naples "Federico II", 80134, Naples, Italy, , Italy; Institute of Crystallography, CNR, Bari, 70126, Institute of Crystallography, CNR, 70126, Bari, Italy, , Italy

Multiple sclerosis (MS) belongs to demyelinating diseases, which are progressive and highly debilitating pathologies that imply a high burden both on individual patients and on so-ciety. Currently, several treatment strategies differ in the route of administration, adverse events, and possible risks. Side effects associated with multiple sclerosis medications range from mild symptoms, such as flu-like or irritation at the injection site, to serious ones, such as progressive multifocal leukoencephalopathy and other life-threatening events. Moreover, the agents so far avail-able have proved incapable of fully preventing disease progression, mostly during the phases that consist of continuous, accumulating disability. Thus, new treatment strategies, able to halt or even reverse disease progression and specific for targeting solely the pathways that contribute to the disease pathogenesis, are highly desirable. Here, we provide an overview of the recent literature about peptide-based systems tested on experimental autoimmune encephalitis (EAE) models. Since peptides are considered a unique therapeutic niche and important elements in the pharmaceutical landscape, they could open up new therapeutic opportunities for the treatment of MS.

Molecules (Basel, Online) 26